New York, NY – Combating patient non-adherence continues to be a significant issue, as associated costs are on the rise and the U.S. moves toward a stronger preventive health agenda. Ipsos is committed to the fight, helping to spark meaningful discussion and develop viable solutions.
In October 2011, Ipsos Healthcare’s Elys Roberts, President, and Paul Snyderman, Chief Research Officer, joined a diverse group of experts for a moderated roundtable meeting that aimed to examine constructive approaches to encourage Americans to take their medications as prescribed. Hosted by Pharmaceutical Executive Magazine in conjunction with the National Consumers League’s (NCL) Script Your Future initiative, the session’s goal was to determine some practical steps for incorporation in the campaign agenda.
“Patient non-adherence is a significant issue on many levels in the U.S., from poor patient outcomes to inefficient and expensive healthcare costs,” says Roberts. “Convening this senior group of stakeholders from different backgrounds and perspectives to generate ideas for the future of this campaign is an important step forward in addressing the issue. Ipsos Healthcare is proud to continue our active involvement in the conversation and working toward solutions.”
Capturing the discussion and input generated during the roundtable meeting, Pharmaceutical Executive published an article – The Medicines Adherence Challenge – in the December 2011 edition of the magazine.
Ipsos Healthcare was the only market research agency involved in the roundtable and has been a proud supporter of the NCL initiative since it first launched in May 2011.
“Medication non-adherence is a complicated problem that at its core is very individualized and requires a sophisticated segmentation solution,” says Snyderman. “Through Ipsos Healthcare’s Adherence Dynamics research approach we are able to identify patient segments in terms of their mal-adherent situations and their specific underlying motivational states. This roundtable discussion was an opportunity to contribute insights from our research and work collaboratively in the effort to improve medication adherence in the U.S.”
To read the full Pharmaceutical Executive article, The Medicines Adherence Challenge, which includes a summary of the main conclusions and relevant comments from participants, please click here.
About the National Consumers League’s Medication Adherence Campaign
The National Consumers League (NCL), with planning funds from the Agency for Healthcare Research and Quality (AHRQ), is organizing a groundbreaking, national multi-media campaign to improve public health by raising consumer awareness of the importance of good medication adherence. The campaign involves a broad cross-section of public and private stakeholders. To learn more about this NCL initiative, click here.
For more information on this news release, please contact:
Chief Research Officer
Ipsos is a leading global survey-based market research company, owned and managed by research professionals. Ipsos helps interpret, simulate, and anticipate the needs and responses of consumers, customers, and citizens around the world.
Member companies assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience responses to various media. They measure public opinion around the globe.
Ipsos member companies offer expertise in advertising, customer loyalty, marketing, media, and public affairs research, as well as forecasting, modeling, and consulting. Ipsos has a full line of custom, syndicated, omnibus, panel, and online research products and services, guided by industry experts and bolstered by advanced analytics and methodologies. The company was founded in 1975 and has been publicly traded since 1999.In 2010, Ipsos generated global revenues of €1.140 billion ($1.6 billion U.S.).
Visit www.ipsos-na.com to learn more about Ipsos
offerings and capabilities.
Ipsos, listed on the Eurolist of Euronext – Comp B, is part of SBF 120 and the Mid-100 Index, adheres to the Next Prime segment and is eligible to the Deferred Settlement System. Isin FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP